Topics

PerkinElmer Announces Redemption of 5% Senior Unsecured Notes Due in 2021

08:00 EDT 13 Sep 2019 | Businesswire
PerkinElmer, Inc.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it is giving notice of the redemption of all of its outstanding 5% Senior Unsecured Notes due in 2021 (the “2021 Notes”).

In accordance with the terms of the indenture governing the 2021 Notes (the “Indenture”), the 2021 Notes will be redeemed on October 13, 2019 (the “Redemption Date”), at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest, discounted to the Redemption Date on a semi-annual basis at the Treasury Rate (as defined in the Indenture), plus 45 basis points. The redemption price will also include, in each case, accrued and unpaid interest on the 2021 Notes to, but excluding, the Redemption Date.

U.S. Bank National Association, the trustee for the 2021 Notes, is delivering a Notice of Redemption to all registered holders of the 2021 Notes today. Copies of such Notice of Redemption and additional information relating to the procedure for redemption of the 2021 Notes may be obtained from U.S. Bank National Association by calling 1-800-934-6802.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.8 billion in 2018, has about 13,000 employees serving customers in more than 180 countries, and is a component of the S&P 500 Index.

Investor Relations:
Bryan Kipp, 781-663-5583
bryan.kipp@perkinelmer.com

Media:
Brian Willinsky, 781-663-5728
brian.willinsky@perkinelmer.com

NEXT ARTICLE

More From BioPortfolio on "PerkinElmer Announces Redemption of 5% Senior Unsecured Notes Due in 2021"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...